Used in targeted cancer therapies, particularly for tumors driven by the KRAS G12D mutation, which is common in pancreatic, colorectal, and lung cancers. This inhibitor selectively targets the mutant KRAS protein, blocking its abnormal signaling that promotes uncontrolled cell growth. By inhibiting this pathway, it helps suppress tumor progression and can enhance the effectiveness of other anticancer treatments. It is primarily used in research settings to develop precision medicines and evaluate response in preclinical models.